Memolan

Memantine Hydrochloride, the active ingredient in Memolan, is a NMDA receptor antagonist presented as a tablet for oral use. It is indicated for the treatment of moderate to severe Alzheimer’s disease in adult patients, helping to improve cognition and functional abilities.

GNH USA supplies Memolan as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to strict quality standards and provides regulatory‑approved batches to meet global demand.

Memolan is used in the management of Alzheimer’s disease, a neurodegenerative disorder affecting memory and cognition.

- Alzheimer's disease (moderate to severe): improves cognitive function and daily living activities in patients with moderate to severe disease. - Behavioral symptoms of Alzheimer’s disease: may reduce agitation, aggression and psychosis associated with the condition. - Dementia due to Alzheimer’s disease: supports maintenance of functional independence in individuals with dementia.

Memolan may cause a range of adverse reactions, which are categorized by frequency.

Common Side Effects: - Dizziness: transient sensation of light‑headedness. - Headache: mild to moderate intensity. - Constipation: reduced bowel movements. - Fatigue: feeling of tiredness. - Hypertension: elevated blood pressure readings.

Serious or Rare Side Effects: - Seizures: convulsive episodes requiring medical attention. - Severe skin reactions: such as Stevens‑Johnson syndrome. - Hepatic injury: abnormal liver function tests. - Cardiac arrhythmias: irregular heart rhythms. - Suicidal thoughts: emergence of depressive ideation.

When prescribing Memolan, clinicians should consider several precautionary measures to ensure safe use.

- Renal impairment: adjust dose or monitor renal function. - Hepatic impairment: use with caution in patients with liver disease. - History of seizures: monitor for increased seizure activity. - Cardiovascular disease: observe blood pressure and heart rate. - Elderly patients: start at low dose and titrate slowly. - Store at room temperature: keep in the original pack, protect from moisture and direct sunlight.

Memolan can interact with other medicines, altering its effectiveness or safety profile.

Major Interactions (Avoid): - Amantadine: combined NMDA antagonism may increase neurotoxicity. - Other NMDA antagonists: additive effects on neuronal inhibition. - Strong renal clearance inhibitors (e.g., NSAIDs): may raise memantine plasma levels.

Moderate Interactions (Monitor Closely): - Anticholinergic agents: may diminish cognitive benefits. - CNS depressants (e.g., benzodiazepines): increased sedation risk. - Antihypertensives: potential additive blood pressure lowering. - Diuretics: monitor electrolyte balance. - Antiepileptic drugs: possible alteration of seizure threshold.